Compare FF & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FF | VYGR |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 212.3M | 203.6M |
| IPO Year | 2005 | 2015 |
| Metric | FF | VYGR |
|---|---|---|
| Price | $4.82 | $2.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 275.9K | ★ 696.7K |
| Earning Date | 05-11-2026 | 05-08-2026 |
| Dividend Yield | ★ 5.32% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $10,135,000.00 |
| Revenue This Year | N/A | $34.04 |
| Revenue Next Year | N/A | $7.92 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.09 | $2.94 |
| 52 Week High | $5.24 | $5.55 |
| Indicator | FF | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 59.10 | 36.14 |
| Support Level | $4.00 | N/A |
| Resistance Level | $5.10 | $4.33 |
| Average True Range (ATR) | 0.21 | 0.17 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 50.00 | 5.80 |
FutureFuel Corp makes and sells diversified chemical products, bio-based fuel products, and specialty chemical products. The company is organized into two segments based on product type: biofuels and chemicals. The biofuels segment sells biodiesel and other petroleum products, with fuels made from a mix of diesel, vegetable oils, and grease feedstock. The chemicals segment, which generates the majority of revenue, sells products used in the production of agricultural chemicals, including herbicides, as well as coatings and cleaning products such as detergents.
Voyager Therapeutics Inc is a biotechnology company to leverage the power of human genetics to modify the course of and ultimately cure neurological diseases. Its pipeline includes programs for Alzheimer's disease, or AD; Friedreich's ataxia, or FA; Parkinson's disease, or PD; and multiple other diseases of the central nervous system, or CNS. Many of its programs are derived from its TRACER (Tropism Redirection of AAV by Cell-type-specific Expression of RNA) adeno-associated virus, or AAV, capsid discovery platform, which the company has used to generate novel capsids, or TRACER Capsids, and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous, or IV, dosing. Its segment is developing and commercializing genetic medicine.